PatientsVille.com Logo

PRODUCT QUALITY ISSUE and Flagyl

PatientsVille

PRODUCT QUALITY ISSUE Symptoms and Causes

We all need clean water. People need it to grow crops and to operate factories, and for drinking and recreation. Fish and wildlife depend on it to survive.

Many different pollutants can harm our rivers, streams, lakes, and oceans. The three most common are soil, nutrients, and bacteria. Rain washes soil into streams and rivers. The soil can kill tiny animals and fish eggs. It can clog the gills of fish and block light, causing plants to die. Nutrients, often from fertilizers, cause problems in lakes, ponds, and reservoirs. Nitrogen and phosphorus make algae grow and can turn water green. Bacteria, often from sewage spills, can pollute fresh or salt water.

You can help protect your water supply:

  • Don't pour household products such as cleansers, beauty products, medicines, auto fluids, paint, and lawn care products down the drain. Take them to a hazardous waste collection site.
  • Throw away excess household grease (meat fats, lard, cooking oil, shortening, butter, margarine, etc.) diapers, condoms, and personal hygiene products in the garbage can.
  • Clean up after your pets. Pet waste contains nutrients and germs.

Environmental Protection Agency

Check out the latest treatments for PRODUCT QUALITY ISSUE

PRODUCT QUALITY ISSUE treatment research studies

Flagyl clinical trials, surveys and public health registries


Find Drug Side Effect reports



Flagyl Side Effects

Diarrhoea (69)
Pyrexia (65)
Paraesthesia (59)
Vomiting (56)
Nausea (53)
Dizziness (51)
Hypoaesthesia (46)
Rash (44)
Pain (44)
Neuropathy Peripheral (43)
Abdominal Pain (43)
Confusional State (41)
Pruritus (37)
Dyspnoea (37)
Weight Decreased (36)
Urticaria (36)
Chills (34)
Thrombocytopenia (32)
Dysgeusia (31)
Headache (29)
Hypersensitivity (29)
Renal Failure Acute (27)
Anxiety (27)
Erythema (26)
Convulsion (26)
Oedema Peripheral (23)
Insomnia (22)
Neutropenia (22)
Asthenia (22)
Cholestasis (22)
Malaise (21)
Fatigue (21)
Anaemia (20)
Burning Sensation (19)
Fall (18)
Gait Disturbance (18)
Arthralgia (18)
Alanine Aminotransferase Increased (17)
Clostridium Difficile Colitis (17)
Abdominal Discomfort (17)
Depression (17)
Toxic Skin Eruption (17)
Muscle Spasms (17)
Hepatitis (16)
Hypotension (16)
Pancreatitis Acute (16)
Pain In Extremity (16)
Tremor (16)
Pancreatitis (15)
Polyneuropathy (15)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I am currenty on Flagyl for a pelvic infection in combination with vibramyacin. This morning I took the vibramyacin and then was planning on taking the Flagyl an hour later, but I spent the this morning vomiting. I called the dr.

I took flagyl for 5 days each day feeling worse nausea an inner agitation and yawning for air difficulty breathing.....felt like it was attacking my intestines and the body was reacting and going into flight or fight. Very uncomfortable really unbear

My son was treated with flagyl and vancomycin for cdiff. Today after 2 weeks off vanco he has mucus in his stool. Does he still have cdiff? What should we do

The exact same thing happened to me after I was prescribed high dose flagyl for 5 days for suspected diverticulitis (painful bloating, frothy yellow diarrhea, excessive foul gas, etc.) my doc also put me on a Clear Liquid Diet for 3 days before I h

Dear Sir/Madam, We are 'Alispo International' from Sialkot Pakistan. As a manufacturer, we supply 'SURGICAL DENTAL HAND INSTRUMENTS' in high quality, including Gynecology, ENT, Ophthalmic, Cardiac, Orthodontic and endodontic instruments. O

i never had an issue with using theraflu before. this time around i feel drunk every time i take it. i feel really super drowsy. and it is not working at all. i am still very congested even though i have a runny nose. i am still sore all over even t

>:o Took my first dose today,it left me covered in a red itchy rash on neck,chest,back and sides within 10 minutes of consuming.This product is now sitting in the trash can. :(

Hey Michelle, we almost have the same issue..I switched from Yaz to Trinessa because I and my husband thought it caused my severe mood swings prior to my period. I have been running and working out but I start experiencing joint

<span style='color: #808080;'><b>Describe Your Nystagmus from DTAP + IPV + HIB (PENTACEL) 2010 Experience Here: My duagters very first set of vaccination shots at 3 months caused nystagmus. We did not notice the issue

'OCAS' means that the product is administered over a time period. For this reason it must be swallowed whole and not chewed.

....however, dalacine is very effective unto face. kaya ngaun patuloy na ang paggamit ko sa product na ito.. try niyo rin para masubukan niyo. sabi nga hindi mo malalaman ang tamis hangat hindi mo nasusubukan ang pa.it....jejejeje' &nb

1.2-methyl-2-butene is treated with the following reagents write the structural formula of the mian organic product in each case

According to unspsc classification ,in which commodity this product fall?

After i use sensordyne , i have extremely pain travel from the back of my throat and uperjaw to my head . I though this product will reduce sensitivity in my teeth , now i have more pain then before.

PRODUCT QUALITY ISSUE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Azithromycin + Metronidazole;   Drug: Metronidazole
Outcome Measures: Response rate at 8 weeks defined as a drop in PCDAI (Pediatric Crohn's Disease Activity Index ) of at least 12.5 points (or remission without steroids, intention to treat principle);   Normalization of CRP ( CRP ≤0.5 mg/dL).;   Fecal calprotectin at 8 weeks .
2 Not yet recruiting Study to Determine the Equivalence of Three Products Containing Metronidazole Benzoate.
Condition: Bacterial Infections
Interventions: Drug: Metronidazole benzoate;   Drug: Flagyl 125 mg/5 ml oral suspension;   Drug: Flagyl 400 mg Tablets
Outcome Measures: Plasma concentration time profiles under the curve (AUC);   Maximum concentration (Cmax);   Time to maximum concentration (Tmax);   Elimination rate constant (Kel);   Terminal half life (t1/2);   Number of participants with Adverse Events
3 Recruiting Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies
Conditions: Abnormal Vaginal Flora;   Clindamycin Vs Metronidazole;   High Risk Pregnancies for Preterm Labor
Interventions: Drug: Clindamycin;   Drug: Metronidazole
Outcome Measures: To compare the efficacy between oral Clindamycin Vs Metronidazole in the eradication of abnormal vaginal flora;   The prevalence of adverse effects;   The prevalence of late abortions and preterm deliveries;   Assessing the correlation between Nugent score , physical examination and Ph indicators
4 Recruiting BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) Study
Condition: Bacterial Vaginosis
Interventions: Drug: Gelatin;   Drug: Boric acid;   Drug: Metronidazole
Outcome Measures: Effectiveness of treatment of intravaginal boric acid and metronidazole at 1 week and 30 days post-treatment will be measured as absence of symptoms or negative vaginal swab (Nugent score less than 7) if symptoms are present for BV.;   If during the 10 days of treatment of intravaginal boric acid and metronidazole the patient discontinues the treatment because of side effects or complained of intolerable side effects this will be considered a treatment failure for safety.
5 Recruiting Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis
Condition: Bacterial Vaginosis
Interventions: Drug: N-Acetyl cysteine;   Drug: Metronidazole + N-Acetyl cysteine;   Drug: metronidazole
Outcome Measures: recovery of BV;   prevention of recurrence
6 Unknown  Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
Condition: Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions: Drug: 10RAC+acetylcystein;   Drug: 10RAC+metronidazole
Outcome Measures: Re-eradication rate;   Influence of Participant's CYP2C19 genotype on re-eradication rate
7 Unknown  Inflammation and Treatment of Bacterial Vaginosis Near Term
Condition: Bacterial Vaginosis
Interventions: Drug: Metronidazole;   Drug: Placebo
Outcome Measure: Levels of Interleukins 1 and 6 as well as Tumor Necrosis Factor Alpha
8 Recruiting Impact of Oral Antibiotic Treatment on C. Difficile
Conditions: C. Difficile;   Diarrhea;   Enterocolitis
Interventions: Drug: Fidaxomicin;   Drug: Metronidazole;   Drug: Vancomycin
Outcome Measures: Change in variation of the profile of C. difficile isolated from specific body sites of a patient with microbiology-proven CDAD;   Change in variation in the profile of C. difficile isolated from targeted surfaces in a hospital;   Extent and quantity of C. difficile shedding, colonization and environmental contamination in patients who received oral fidaxomicin vs. oral metronidazole or vancomycin;   Duration of diarrhea that were positive for CDAD
9 Unknown  Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses
Condition: Abscess, Intra-Abdominal
Intervention: Drug: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam
Outcome Measures: Clinical success / failure rate at the Test-of-Cure visit;   Clinical + Bacteriological response at End-of-Treatment-visit;   Time to discharge from hospital;   Course of disease on the basis of clinical and laboratory parameters;   safety and tolerability of the study medication;   cost effectiveness of treatment regimes
10 Recruiting Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy
Condition: Helicobacter Pylori Infection
Interventions: Drug: pantoprazole, amoxicillin, clarithromycin, metronidazole;   Drug: pantoprazole, amoxicillin, clarithromycin, metronidzole
Outcome Measure: Comparison of the eradications rates of sequential therapy versus concomitant therapy of treatment of Helicobacter pylori infection in Korea.
11 Recruiting Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI;   Drug: Metronidazole;   Drug: Meropenem
Outcome Measures: Clinical Cure as Measured by proportion of patients meeting cure criteria in the microbiological modified Intent-To-Treat analysis set.;   The proportion of patients with clinical cure in the microbiologically evaluable and extended microbiologically evaluable analysis set;   The proportion of patients with clinical cure in the microbiological modified intent-to-treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets;   The proportion of patients with clinical cure in the clinically evaluable analysis set.;   The proportion of patients with a favorable per-patient microbiological response in the microbiological modified intent to treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets;   The proportion of favorable per-pathogen microbiological response in the microbiological modified intent to treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets;   The favorable per-pathogen microbiologic response by minimum inhibitory concentration (MIC) categories in the microbiological modified intent to treat, microbiologically evaluable, and extended microbiologically evaluable analysis sets;   Favorable per-patient clinical response & microbiological response for patients infected with ceftazidime-resistant pathogens in microbiological modified intent to treat, microbiologically evaluable & extended microbiologically evaluable analysis sets;   Proportion of patients with favorable per-pathogen microbiological response for patients infected with ceftazidime-resistant pathogens in microbiological modified ITT, microbiologically evaluable and extended microbiologically evaluable analysis sets;   The time to first defervescence in the clinically evaluable, microbiologically evaluable, and extended microbiologically evaluable analysis sets for patients who have fever at study entry;   The safety and tolerability by incidence and severity of adverse events and serious adverse events, vital signs, clinical laboratory tests, ECGs and physical exams.;   Pharmacokinetics: maximum concentration (Cmax), minimum concentration, area under the plasma concentration time curve at steady state, and terminal half-life
12 Recruiting Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
Condition: Complicated Intra-abdominal Infection
Interventions: Drug: Ceftazidime-avibactam;   Drug: metronidazole;   Drug: Meropenem
Outcome Measures: The proportion of patients with clinical cure in the clinically evaluable analysis set;   The proportion of patients with clinical cure in the microbiologically evaluable, extended microbiologically evaluable and microbiological modified intent-to-treat analysis sets;   The proportion of patients with a favorable per-patient microbiological response in the microbiological modified intent to treat, microbiologically evaluable and extended microbiologically evaluable analysis sets;   The proportion of favorable per-pathogen microbiological response in the microbiological modified intent to treat, microbiologically evaluable and extended microbiologically evaluable analysis sets;   The favorable per-pathogen microbiologic response by minimum inhibitory concentration categories in the microbiological modified intent to treat, microbiologically evaluable and extended microbiologically evaluable analysis sets;   Favorable clinical response and favorable per-patient microbiological response for patients infected with ceftazidime-resistant pathogens in the microbiological modified intent to treat and (extended) microbiologically evaluable analysis sets;   The proportion of patients with a favorable per-pathogen microbiological response for patients infected with ceftazidime-resistant pathogens in the microbiological modified intent to treat and (extended) microbiologically evaluable analysis sets;   The time to first defervescence in the clinically evaluable, microbiologically evaluable and extended microbiologically evaluable analysis sets for patients who have fever at study entry;   Safety and tolerability by incidence and severity of adverse events and serious adverse events, exposure, mortality, reasons for discontinuations of study therapy, vital signs, laboratory tests, electrocardiogram parameters and physical exams
13 Unknown  Effects of the Variation in the Time of Systemic Administration of Metronidazole and Amoxicillin Associated to the Non-surgical Therapy of Chronic Periodontitis.
Conditions: Chronic Periodontitis;   Clinical and Microbiological Effects
Intervention: Drug: Administration of Metronidazole plus Amoxicillin
Outcome Measures: - Mean change in clinical attachment level (CAL);   - Mean change in probing pocket depths (PD)
14 Recruiting The Use of Erythritol Powder and Metronidazole Gel for the Non-surgical Treatment of Periodontitis
Condition: Periodontal Pocket
Interventions: Drug: metronidazole gel;   Procedure: ultrasonics;   Procedure: erythritol;   Drug: placebo
Outcome Measures: Probing pocket Depth change;   Bleeding on Probing change;   Clinical Attachment level change
15 Not yet recruiting Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy
Conditions: Prostate Cancer;   Prostatic Neoplasms;   Neoplasms, Prostate
Interventions: Biological: PROSTVAC-V/TRICOM;   Biological: PROSTVAC-F/TRICOM
Outcome Measures: Changes from baseline to after surgery of CD4 and CD8 cell infiltrates;   Change in peripheral PSA-specific T cells;   Any intraprostatic Treg cell infiltration with CD4+FOX-P3 staining;   Any PSA changes secondary to vaccination;   Any MRI changes secondary to vaccination
16 Unknown  The Impact of Obesity on Nonsurgical Periodontal Therapy
Conditions: Periodontitis;   Periodontal Diseases;   Obesity
Interventions: Drug: Metronidazole;   Drug: Placebo;   Procedure: Scaling and root planning
Outcome Measures: Probing depth;   Attachment level
17 Recruiting Concomitant Therapy of H. Pylori
Condition: Gastritis, Gastric Ulcer, and Duodenal Ulcer
Intervention: Drug: amoxicillin, clarithromycin, metronidazole, rabeprazole
Outcome Measure: Evaluation of the efficacy of concomitant therapy for eradication of Helicobacter pylori
18 Recruiting Antibiotic Safety (SCAMP)
Condition: Complicated Intra Abdominal Infections
Interventions: Drug: ampicillin and metronidazole and gentamicin;   Drug: ampicillin and gentamicin and clindamycin;   Drug: gentamicin and Piperacillin- tazobactam;   Drug: standard of care antibiotics and metronidazole
Outcome Measures: Death;   Number of participants with therapeutic success at Day 30 and Day 90
19 Recruiting Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: PROSTVAC-F/TRICOM;   Biological: PROSTVAC-V/TRICOM;   Drug: Enzalutamide (Xtandi)
Outcome Measures: Decrease in tumor re-growth rate;   Immune response;   Determine impact on PSA
20 Recruiting Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population
Conditions: Vaginosis, Bacterial;   Infertility;   Miscarriage
Interventions: Drug: Metronidazole;   Drug: Placebo
Outcome Measures: Biochemical Pregnancy Rate (Positive Pregnancy Test);   Pregnancy Rate (Pregnancy Visible on Ultrasound);   Miscarriage Rate (Loss of a Clinically Recognized Pregnancy);   Infectious Morbidity (i.e. Chorioamnionitis, Neonatal Sepsis)